Agence France Presse (03.30.12) - Wednesday, April 04, 2012
Medical trials that aim to shorten the duration of TB
treatment are underway in South Africa, according to
"Fighting tuberculosis is going to require new strategies,"
said Gavin Churchyard, CEO of the independent research body
the Aurum Institute. "The ongoing trial aimed at reducing the
treatment period from six to four months is one of the new
strategies of fighting the disease."
The TB Research Center, which is based in a public hospital in
the Tembisa township east of Johannesburg, is the trial site.
Tembisa has a high TB infection rate.
Many TB patients fail to complete treatment due to difficulty
adhering to the months-long regimen and tolerating the
medicines' side effects. "The long period of treatment has
been identified as one of the reasons for poor adherence,
resulting in drug-resistant TB strains, which are more
expensive to treat," said Christopher Viehbacher, CEO of the
French pharmaceutical firm Sanofi.
Aurum has partnered with Sanofi to increase TB research
capacity. "No organization can work alone to make a meaningful
contribution towards eliminating the disease," said